1985
Abnormal coagulation results in patients with hodgkin's disease
Seifter E, Parker R, Gralnick H, Wesley M, DeVita V, Young R, Longo D. Abnormal coagulation results in patients with hodgkin's disease. The American Journal Of Medicine 1985, 78: 942-950. PMID: 3160235, DOI: 10.1016/0002-9343(85)90216-5.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProthrombin timeAbnormal coagulation test resultsAbnormal coagulation resultsAbnormal test valuesComplete staging evaluationProthrombin time prolongationCoagulation test resultsCourse of diseaseCoagulation factor disordersPartial thromboplastin timeAlkaline phosphatase levelsClotting abnormalitiesAdvanced diseaseConstitutional symptomsMediastinal involvementStaging evaluationCoagulation abnormalitiesAbnormal coagulationEvaluable casesTumor regressionThromboplastin timeFactor disordersHematologic testingInvasive procedures
1975
American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival
Arseneau J, Canellos G, Banks P, Berard C, Gralnick H, DeVita V. American Burkitt's lymphoma: A clinicopathologic study of 30 cases I. Clinical factors relating to prolonged survival. The American Journal Of Medicine 1975, 58: 314-321. PMID: 1115074, DOI: 10.1016/0002-9343(75)90597-5.Peer-Reviewed Original ResearchConceptsLDH levelsTumor massComplete remissionIU/Central nervous system involvementSerum lactic dehydrogenase levelsMonths of treatmentNervous system involvementSerum LDH levelsAmerican Burkitt's lymphomaResults of therapyLactic dehydrogenase levelsLarge tumor massParenteral cyclophosphamideClinical characteristicsClinicopathologic studyLocalized diseaseClinical factorsComplete responseFrequent siteSystem involvementTumor regressionDehydrogenase levelsSudden deathBurkitt's lymphoma
1972
Clinical study with bleomycin: Tolerance to twice weekly dosage
Ohnuma T, Selawry O, Holland J, DeVita V, Shedd D, Hansen H, Muggia F. Clinical study with bleomycin: Tolerance to twice weekly dosage. Cancer 1972, 30: 914-922. PMID: 4116909, DOI: 10.1002/1097-0142(197210)30:4<914::aid-cncr2820300409>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaDose levelsObjective tumor responseBody surface areaTherapeutic dose levelsOptimal dose levelNew antineoplastic agentsPulmonary infiltratesTransient hypertensionUrinary burningAbdominal distentionComplete remissionHematologic toxicityCutaneous toxicityWeekly dosesProlonged courseAdditional patientsPatient toleranceSkin toxicityMalignant neoplasmsTesticular carcinomaTumor responseTumor regressionWeekly dosage